TRIAL RESULTS · SIDE EFFECTS
Carfilzomib side effects
ANSWER
29 trials of Carfilzomib posted side-effect results, none against placebo, so no placebo rate exists to compare. Most reported: anaemia, fatigue, diarrhoea. Read from ClinicalTrials.gov on 2026-10-03. Not medical advice.
Trial register
Trials with posted results
29
with an arm on Carfilzomib, of 308 registered
Against placebo
0
placebo-controlled trials
People in those trials
0
on Carfilzomib · 0 on placebo
Read
2026-10-03
ClinicalTrials.gov
ALL TRIALS
The 100 most reported of 1827 side effects reported
Every trial with posted results and an arm on Carfilzomib (n ≥ 20), all phases, by people affected. Placebo is shown where placebo-controlled trials reported the same event. Comparator arms are not counted.
| Side effect | Organ system | Carfilzomib | Placebo | Trials |
|---|---|---|---|---|
| Anaemia | Blood and lymphatic system disorders | 34.9% (1,178 of 3,374) | - | 17 |
| Fatigue | General disorders | 31.2% (1,159 of 3,714) | - | 24 |
| Diarrhoea | Gastrointestinal disorders | 28.8% (972 of 3,374) | - | 17 |
| Nausea | Gastrointestinal disorders | 26.6% (946 of 3,562) | - | 21 |
| Hypertension | Vascular disorders | 22.7% (860 of 3,790) | - | 24 |
| Thrombocytopenia | Blood and lymphatic system disorders | 24.6% (843 of 3,432) | - | 18 |
| Pyrexia | General disorders | 24.0% (809 of 3,374) | - | 17 |
| Cough | Respiratory, thoracic and mediastinal disorders | 21.2% (743 of 3,503) | - | 18 |
| Upper respiratory tract infection | Infections and infestations | 22.5% (667 of 2,970) | - | 14 |
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | 20.5% (659 of 3,212) | - | 15 |
| Insomnia | Psychiatric disorders | 19.3% (655 of 3,402) | - | 17 |
| Neutropenia | Blood and lymphatic system disorders | 18.4% (608 of 3,309) | - | 17 |
| Headache | Nervous system disorders | 17.7% (602 of 3,394) | - | 18 |
| Vomiting | Gastrointestinal disorders | 15.8% (559 of 3,544) | - | 19 |
| Constipation | Gastrointestinal disorders | 14.3% (515 of 3,610) | - | 21 |
| Back pain | Musculoskeletal and connective tissue disorders | 16.0% (495 of 3,101) | - | 17 |
| Oedema peripheral | General disorders | 16.4% (488 of 2,970) | - | 14 |
| Asthenia | General disorders | 14.7% (471 of 3,212) | - | 15 |
| Pneumonia | Infections and infestations | 12.2% (422 of 3,471) | - | 19 |
| Arthralgia | Musculoskeletal and connective tissue disorders | 12.3% (416 of 3,372) | - | 17 |
| Nasopharyngitis | Infections and infestations | 11.7% (383 of 3,260) | - | 15 |
| Hypokalaemia | Metabolism and nutrition disorders | 12.9% (378 of 2,941) | - | 13 |
| Bronchitis | Infections and infestations | 11.8% (351 of 2,980) | - | 14 |
| Platelet count decreased | Investigations | 17.7% (339 of 1,910) | - | 16 |
| Muscle spasms | Musculoskeletal and connective tissue disorders | 14.6% (323 of 2,216) | - | 11 |
| Pain in extremity | Musculoskeletal and connective tissue disorders | 10.2% (315 of 3,089) | - | 16 |
| Rash | Skin and subcutaneous tissue disorders | 9.6% (301 of 3,123) | - | 16 |
| Dizziness | Nervous system disorders | 11.0% (297 of 2,711) | - | 13 |
| Blood creatinine increased | Investigations | 9.5% (269 of 2,817) | - | 12 |
| Hyperglycaemia | Metabolism and nutrition disorders | 7.7% (258 of 3,335) | - | 16 |
| Decreased appetite | Metabolism and nutrition disorders | 9.5% (256 of 2,690) | - | 11 |
| Neutrophil count decreased | Investigations | 11.4% (241 of 2,117) | - | 14 |
| Chills | General disorders | 8.9% (224 of 2,529) | - | 14 |
| Hypocalcaemia | Metabolism and nutrition disorders | 9.8% (223 of 2,278) | - | 10 |
| Leukopenia | Blood and lymphatic system disorders | 8.9% (208 of 2,333) | - | 12 |
| Lymphopenia | Blood and lymphatic system disorders | 17.2% (205 of 1,191) | - | 7 |
| ANAEMIA | Blood and lymphatic system disorders | 42.3% (196 of 463) | - | 1 |
| Bone pain | Musculoskeletal and connective tissue disorders | 7.4% (192 of 2,585) | - | 14 |
| Anemia | Blood and lymphatic system disorders | 49.9% (189 of 379) | - | 8 |
| Pruritus | Skin and subcutaneous tissue disorders | 7.8% (177 of 2,277) | - | 12 |
| Alanine aminotransferase increased | Investigations | 5.9% (174 of 2,946) | - | 16 |
| Neuropathy peripheral | Nervous system disorders | 7.7% (172 of 2,245) | - | 10 |
| DIARRHOEA | Gastrointestinal disorders | 36.1% (167 of 463) | - | 1 |
| Cataract | Eye disorders | 7.7% (166 of 2,143) | - | 12 |
| Urinary tract infection | Infections and infestations | 5.3% (162 of 3,056) | - | 16 |
| Diarrhea | Gastrointestinal disorders | 37.5% (160 of 427) | - | 8 |
| Respiratory tract infection | Infections and infestations | 6.6% (152 of 2,296) | - | 8 |
| Lymphocyte count decreased | Investigations | 33.8% (150 of 444) | - | 7 |
| Influenza | Infections and infestations | 5.1% (149 of 2,919) | - | 14 |
| FATIGUE | General disorders | 32.2% (149 of 463) | - | 1 |
| HYPERTENSION | Vascular disorders | 32.0% (148 of 463) | - | 1 |
| Myalgia | Musculoskeletal and connective tissue disorders | 5.8% (147 of 2,554) | - | 12 |
| Abdominal pain | Gastrointestinal disorders | 6.7% (147 of 2,189) | - | 10 |
| Peripheral sensory neuropathy | Nervous system disorders | 7.6% (146 of 1,920) | - | 10 |
| PYREXIA | General disorders | 31.1% (144 of 463) | - | 1 |
| DYSPNOEA | Respiratory, thoracic and mediastinal disorders | 31.1% (144 of 463) | - | 1 |
| Dyspepsia | Gastrointestinal disorders | 6.2% (140 of 2,250) | - | 12 |
| Hypophosphataemia | Metabolism and nutrition disorders | 7.9% (134 of 1,687) | - | 8 |
| Anxiety | Psychiatric disorders | 6.1% (130 of 2,146) | - | 13 |
| Dyspnea | Respiratory, thoracic and mediastinal disorders | 29.7% (130 of 438) | - | 7 |
| White blood cell count decreased | Investigations | 11.6% (128 of 1,104) | - | 6 |
| COUGH | Respiratory, thoracic and mediastinal disorders | 27.6% (128 of 463) | - | 1 |
| Pain | General disorders | 7.5% (126 of 1,680) | - | 12 |
| Hyperuricaemia | Metabolism and nutrition disorders | 6.0% (126 of 2,095) | - | 7 |
| INSOMNIA | Psychiatric disorders | 27.0% (125 of 463) | - | 1 |
| Acute kidney injury | Renal and urinary disorders | 4.4% (119 of 2,716) | - | 17 |
| Hypomagnesaemia | Metabolism and nutrition disorders | 9.8% (119 of 1,220) | - | 7 |
| Upper Respiratory Tract Infection | Infections and infestations | 32.1% (117 of 365) | - | 2 |
| Hyperglycemia | Metabolism and nutrition disorders | 28.6% (116 of 405) | - | 7 |
| OEDEMA PERIPHERAL | General disorders | 25.1% (116 of 463) | - | 1 |
| UPPER RESPIRATORY TRACT INFECTION | Infections and infestations | 25.1% (116 of 463) | - | 1 |
| Epistaxis | Respiratory, thoracic and mediastinal disorders | 4.1% (112 of 2,757) | - | 11 |
| White blood cell decreased | Investigations | 44.1% (112 of 254) | - | 5 |
| Productive cough | Respiratory, thoracic and mediastinal disorders | 5.8% (110 of 1,894) | - | 10 |
| Paraesthesia | Nervous system disorders | 6.1% (109 of 1,779) | - | 10 |
| Aspartate aminotransferase increased | Investigations | 6.7% (108 of 1,619) | - | 13 |
| NAUSEA | Gastrointestinal disorders | 23.3% (108 of 463) | - | 1 |
| ASTHENIA | General disorders | 23.1% (107 of 463) | - | 1 |
| Hypophosphatemia | Metabolism and nutrition disorders | 26.2% (106 of 405) | - | 7 |
| Hypotension | Vascular disorders | 3.5% (105 of 2,974) | - | 17 |
| BACK PAIN | Musculoskeletal and connective tissue disorders | 22.7% (105 of 463) | - | 1 |
| BRONCHITIS | Infections and infestations | 22.2% (103 of 463) | - | 1 |
| Sinusitis | Infections and infestations | 4.6% (102 of 2,219) | - | 11 |
| THROMBOCYTOPENIA | Blood and lymphatic system disorders | 21.6% (100 of 463) | - | 1 |
| HEADACHE | Nervous system disorders | 20.5% (95 of 463) | - | 1 |
| Hypercalcaemia | Metabolism and nutrition disorders | 3.7% (94 of 2,549) | - | 10 |
| Hyponatraemia | Metabolism and nutrition disorders | 4.3% (92 of 2,148) | - | 9 |
| Anorexia | Metabolism and nutrition disorders | 13.4% (92 of 685) | - | 5 |
| Muscular weakness | Musculoskeletal and connective tissue disorders | 8.6% (92 of 1,071) | - | 5 |
| MUSCLE SPASMS | Musculoskeletal and connective tissue disorders | 19.9% (92 of 463) | - | 1 |
| Infection | Infections and infestations | 3.5% (89 of 2,559) | - | 11 |
| Dyspnoea exertional | Respiratory, thoracic and mediastinal disorders | 4.8% (87 of 1,812) | - | 10 |
| Hypoaesthesia | Nervous system disorders | 5.4% (85 of 1,568) | - | 8 |
| Infusion Related Reaction | Injury, poisoning and procedural complications | 28.1% (84 of 299) | - | 1 |
| Viral upper respiratory tract infection | Infections and infestations | 14.6% (81 of 556) | - | 2 |
| NASOPHARYNGITIS | Infections and infestations | 17.5% (81 of 463) | - | 1 |
| Back Pain | Musculoskeletal and connective tissue disorders | 21.6% (79 of 365) | - | 2 |
| Sepsis | Infections and infestations | 2.2% (78 of 3,474) | - | 19 |
| CONSTIPATION | Gastrointestinal disorders | 16.2% (75 of 463) | - | 1 |
| VOMITING | Gastrointestinal disorders | 16.2% (75 of 463) | - | 1 |
Source: ClinicalTrials.gov posted results, read 2026-10-03. A trial lists events above its own reporting threshold, so a rare event may be missing from some trials. Not medical advice.
FDA LABEL
What the FDA label says
KYPROLIS NDA202714 · label of 2025-06-18 Regulator
The most common adverse reactions occurring in at least 20% of patients treated with Kyprolis in monotherapy trials: anemia, fatigue, thrombocytopenia, nausea, pyrexia, dyspnea, diarrhea, headache, cough, edema peripheral.
REGISTERED STUDIES
308 registered clinical trials of Carfilzomib
The 10 most recently updated are listed.
| NCT04925193 | Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma Status: ACTIVE_NOT_RECRUITING · Updated 2026-10-02 |
|---|---|
| NCT07715903 | Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy Status: NOT_YET_RECRUITING · Updated 2026-10-02 |
| 2024-515279-37-00 | A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) Status: UNKNOWN · Updated 2026-09-30 |
| NCT06948084 | Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse Status: RECRUITING · Updated 2026-09-30 |
| NCT01559935 | Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma Status: COMPLETED · Updated 2026-09-29 |
| NCT06055075 | A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma Status: TERMINATED · Updated 2026-09-29 |
| NCT07222761 | A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) Status: RECRUITING · Updated 2026-09-29 |
| NCT07391657 | A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) Status: RECRUITING · Updated 2026-09-29 |
| NCT07605416 | Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial Status: RECRUITING · Updated 2026-09-29 |
| 2023-503444-13-00 | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide Status: UNKNOWN · Updated 2026-09-28 |
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.